Brooks Laboratories (BROOKS) Stock Overview
Provides contract development and manufacturing services for pharmaceutical companies in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BROOKS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Brooks Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹55.98 |
| 52 Week High | ₹164.02 |
| 52 Week Low | ₹36.30 |
| Beta | 0.81 |
| 1 Month Change | 4.87% |
| 3 Month Change | -10.03% |
| 1 Year Change | -57.35% |
| 3 Year Change | -12.46% |
| 5 Year Change | -32.64% |
| Change since IPO | 761.23% |
Recent News & Updates
Recent updates
Brooks Laboratories Limited (NSE:BROOKS) Not Doing Enough For Some Investors As Its Shares Slump 31%
Dec 31
Impressive Earnings May Not Tell The Whole Story For Brooks Laboratories (NSE:BROOKS)
Nov 22Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?
Sep 28Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?
Jun 10Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)
Feb 22Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?
Dec 08Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?
Jul 07Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt
Jan 05Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt
Sep 22
Shareholder Returns
| BROOKS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -17.1% | 2.6% | 0.4% |
| 1Y | -57.4% | 4.9% | 4.0% |
Return vs Industry: BROOKS underperformed the Indian Life Sciences industry which returned 4.9% over the past year.
Return vs Market: BROOKS underperformed the Indian Market which returned 4% over the past year.
Price Volatility
| BROOKS volatility | |
|---|---|
| BROOKS Average Weekly Movement | 15.0% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: BROOKS's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: BROOKS's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 323 | n/a | www.brookslabs.net |
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs.
Brooks Laboratories Limited Fundamentals Summary
| BROOKS fundamental statistics | |
|---|---|
| Market cap | ₹1.65b |
| Earnings (TTM) | ₹216.03m |
| Revenue (TTM) | ₹888.46m |
Is BROOKS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BROOKS income statement (TTM) | |
|---|---|
| Revenue | ₹888.46m |
| Cost of Revenue | ₹549.62m |
| Gross Profit | ₹338.84m |
| Other Expenses | ₹122.81m |
| Earnings | ₹216.03m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.33 |
| Gross Margin | 38.14% |
| Net Profit Margin | 24.31% |
| Debt/Equity Ratio | 6.8% |
How did BROOKS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 15:01 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Brooks Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |